Cynata Therapeutics Limited
CYYNF
$0.118
$0.01615.69%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -22.62% | -20.82% | -54.69% | -51.10% | 40.07% |
| Total Revenue | -22.62% | -20.82% | -54.69% | -51.10% | 40.07% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -22.62% | -20.82% | -54.69% | -51.10% | 40.07% |
| SG&A Expenses | -24.81% | -23.05% | 2.12% | 4.53% | 1.63% |
| Depreciation & Amortization | -2.63% | -0.43% | -1.28% | -3.35% | -0.65% |
| Other Operating Expenses | 4.27% | 6.71% | -45.42% | -46.75% | -5.03% |
| Total Operating Expenses | -20.71% | -18.86% | -43.72% | -45.11% | 0.70% |
| Operating Income | 19.63% | 17.76% | 42.23% | 43.66% | 13.02% |
| Income Before Tax | 19.63% | 17.76% | 43.62% | 45.01% | 13.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.63% | 17.76% | 43.62% | 45.01% | 13.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.63% | 17.76% | 43.62% | 45.01% | 13.02% |
| EBIT | 19.63% | 17.76% | 42.23% | 43.66% | 13.02% |
| EBITDA | 20.19% | 18.32% | 42.83% | 44.24% | 13.35% |
| EPS Basic | 20.73% | 20.48% | 54.11% | 55.19% | 31.09% |
| Normalized Basic EPS | 23.08% | 21.15% | 53.49% | 55.30% | 29.73% |
| EPS Diluted | 20.73% | 20.48% | 54.11% | 55.19% | 31.09% |
| Normalized Diluted EPS | 23.08% | 21.15% | 53.49% | 55.30% | 29.73% |
| Average Basic Shares Outstanding | 2.70% | 2.70% | 22.39% | 22.39% | 25.26% |
| Average Diluted Shares Outstanding | 2.70% | 2.70% | 22.39% | 22.39% | 25.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |